On April 14, 2016 Portola Pharmaceuticals (Nasdaq:PTLA) reported that new data from a pharmacokinetic modeling study designed to identify the dose of cerdulatinib for expansion cohorts in a Phase 2 study will be presented in a poster session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2016, which is taking place from April 16-20 in New Orleans (Press release, Portola Pharmaceuticals, APR 14, 2016, View Source;p=RssLanding&cat=news&id=2157123 [SID:1234510817]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies. Portola is evaluating cerdulatinib in an ongoing Phase 1/2 study in patients with relapsed/refractory B-cell malignancies who have failed multiple therapies.

The abstract will be made available at www.AACR.org.

Poster Presentation Details

Abstract Title (#CT144): Preclinical and clinical studies and modeling and simulation to identify Phase 2 dose for cerdulatinib: a dual SYK/JAK inhibitor for the treatment of B-cell malignancies
Presenting Author: Janet M. Leeds, Ph.D., Senior Director, Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals

Poster Session Title: Phase I Clinical Trials 2
Presentation Date and Time: Wednesday, April 20, 7:30 a.m. – 11 a.m. Central Time
Location: Ernest N. Morial Convention Center, Halls G-J, Poster Section 13